Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

As regards Pfizer, oncology sales comprise around 25% of ... But which one is a better investment today? Let’s take a closer look at their fundamentals, growth prospects and challenges to ...

The company's strategic pivot to oncology, particularly through ... substantial income while waiting for the investment thesis to play out, Pfizer offers one of the most attractive risk-reward ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pfizer is licensing a promising investigational cancer medicine from a smaller company. This move improves the drugmaker's already attractive oncology pipeline. Pfizer should eventually bounce ...